Evommune (EVMN) Net Margin (2025)
Evommune (EVMN) reported Net Margin of 124.75% for Q3 2025, up 74.07% on a QoQ basis from 481.07% in Q1 2025.
Evommune (EVMN) has 1 years of Net Margin data on file, last reported at 124.75% in Q3 2025.
- Quarterly Net Margin changed N/A year-over-year to 124.75% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 591.18% (changed N/A YoY) and the FY2025 annual result came in at 598.45%, up 35595.0% from the prior year.
- Net Margin improved to 124.75% in Q3 2025 per EVMN's latest filing, from 481.07% in the prior quarter.
- Across five years, Net Margin topped out at 124.75% in Q3 2025 and bottomed at 481.07% in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.65% |
| 10 | Evommune | 782.16 Mn | 570.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -124.75% |
| Mar 31, 2025 | -481.07% |